Europeiska unionen - portugisiska - EMA (European Medicines Agency)

novartis europharm limited  - onasemnogene abeparvovec - atrofia muscular, espinhal - outras drogas para distúrbios do sistema músculo-esquelético - zolgensma é indicado para o tratamento de pacientes com síndrome 5q a atrofia muscular espinhal (sma), com um bi-alélica mutação no gene smn1 e um diagnóstico clínico de sma tipo 1, orpatients com 5q sma com um bi-alélica mutação no gene smn1 e até 3 cópias do gene smn2.

Europeiska unionen - portugisiska - EMA (European Medicines Agency)

novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - asma - medicamentos para obstrutiva, doenças das vias respiratórias, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

Europeiska unionen - portugisiska - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol, mometasone furoate - asma - medicamentos para obstrutiva, doenças das vias respiratórias, - bemrist breezhaler is indicated as a maintenance   treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Europeiska unionen - portugisiska - EMA (European Medicines Agency)

novartis europharm limited - glycopyrronium bromide, indacaterol (acetate), mometasone furoate - asma - medicamentos para obstrutiva, doenças das vias respiratórias, - maintenance treatment of asthma in adults whose disease is not adequately controlled.

Europeiska unionen - portugisiska - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - anemia, célula falciforme - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Europeiska unionen - portugisiska - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - carcinoma, pulmão de células não pequenas - agentes antineoplásicos - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

Europeiska unionen - portugisiska - EMA (European Medicines Agency)

novartis europharm limited - travoprost - ocular hypertension; glaucoma, open-angle - ophthalmologicals, antiglaucoma preparations and miotics - diminuição da pressão intraocular elevada em pacientes adultos com hipertensão ocular ou glaucoma de ângulo aberto (ver seção 5. diminuição da pressão intra-ocular elevada em pacientes pediátricos com idade de 3 anos < 18 anos, com hipertensão ocular ou glaucoma pediátrico.

Europeiska unionen - portugisiska - EMA (European Medicines Agency)

novartis europharm limited  - gozetotide - imagem de radionuclídeos - radiofármaco de diagnóstico - este medicamento é apenas para uso diagnóstico. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.

Europeiska unionen - portugisiska - EMA (European Medicines Agency)

novartis europharm limited  - lutetium (177lu) vipivotide tetraxetan - prostática benigna neoplasias, a castração-resistente - rádiofarmacêutica terapêutica - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.

Europeiska unionen - portugisiska - EMA (European Medicines Agency)

novartis europharm limited - tislelizumab - esophageal squamous cell carcinoma - agentes antineoplásicos - oesophageal squamous cell carcinoma (oscc) tevimbra as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapy.